UK markets close in 7 hours 17 minutes

Perspective Therapeutics, Inc. (CATX)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
1.7600-0.0800 (-4.35%)
At close: 04:00PM EDT
1.7700 +0.01 (+0.57%)
After hours: 07:43PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.03B
Enterprise value 1.03B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)13.74
Enterprise value/revenue 68.73
Enterprise value/EBITDA -26.26

Trading information

Stock price history

Beta (5Y monthly) 1.43
52-week change 3170.77%
S&P500 52-week change 325.59%
52-week high 31.9000
52-week low 30.2100
50-day moving average 31.3690
200-day moving average 30.6684

Share statistics

Avg vol (3-month) 34.39M
Avg vol (10-day) 34.59M
Shares outstanding 5586.92M
Implied shares outstanding 6586.92M
Float 8354.17M
% held by insiders 123.42%
% held by institutions 115.04%
Shares short (15 Apr 2024) 410.43M
Short ratio (15 Apr 2024) 41.62
Short % of float (15 Apr 2024) 42.24%
Short % of shares outstanding (15 Apr 2024) 41.78%
Shares short (prior month 15 Mar 2024) 41.88M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-2,855.02%

Management effectiveness

Return on assets (ttm)-32.81%
Return on equity (ttm)-57.70%

Income statement

Revenue (ttm)1.43M
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -39.96M
Net income avi to common (ttm)-37.45M
Diluted EPS (ttm)-0.1400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)9.24M
Total cash per share (mrq)0.02
Total debt (mrq)2.55M
Total debt/equity (mrq)3.39%
Current ratio (mrq)1.08
Book value per share (mrq)0.27

Cash flow statement

Operating cash flow (ttm)-36.91M
Levered free cash flow (ttm)-8.27M